Enterprise Value
-7.481M
Cash
20.63M
Avg Qtr Burn
-6.747M
Short % of Float
1.96%
Insider Ownership
1.40%
Institutional Own.
11.08%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Zilxi (Minocycline) Details Rosacea | Approved Quarterly sales | |
Amzeeq (minocycline) Details Acne vulgaris | Approved Quarterly sales | |
VYN201 Details Vitiligo | Phase 1b Data readout | |
FMX114 (tofacitinib and fingolimod) Details Atopic dermatitis | Failed Discontinued | |
FCD105 (minocycline & adapalene) Details Acne vulgaris | Failed Discontinued |